183 results on '"Butta, Nora V."'
Search Results
2. Procoagulant State of Sleep Apnea Depends on Systemic Inflammation and Endothelial Damage
3. Pro-apoptotic properties and mitochondrial functionality in platelet-like-particles generated from low Aspirin-incubated Meg-01 cells
4. No changes in haemostasis after COVID-19-heterologous vaccination schedule: a sub analysis of the phase 2 CombiVacS study
5. Relationship between Molecular Profile and Platelet Function and Thrombin Generation in Patients with Essential Thrombocytemia
6. Follow-up and Evaluation of the Efficacy of the Hemostatic Treatment in Congenital FVII Deficiency during Development of Inhibitor
7. Perioperative Monitoring with Global Coagulation Test in Severe Hemophilia a without Inhibitor on Emicizumab Prophylaxis Undergoing Orthopedic Surgery
8. Discontinuation of Thrombopoietin Receptor Agonists: A 10 Year Real-World Experience from an Academic Hospital in Madrid
9. Predictive Value of Platelet Sequestration Studies in Splenectomy Response
10. Effect of a COVID-19-Heterologous Vaccination Schedule on Haemostasis: A Subanalysis of the Phase 2, Multicentre, Randomised, Controlled CombiVacS Study
11. Thrombopoietin receptor agonists in conjunction with oseltamivir for immune thrombocytopenia
12. Evaluation of Global Coagulation Tests for Monitoring Bleeding Phenotypes and Response to Treatments in FVII Deficiency
13. Glycomic Characterization of Platelets from Patients with Immune Thrombocytopenia
14. Evaluation of Platelet Function Defects in Patients with Immune Thrombocytopenia
15. Laboratory Characterization of Unclassified Bleeding Disorders By Non-Conventional Tests
16. Ex Vivo Evaluation of the Effect of Plasma-Derived Factor VIII/Von Willebrand Factor in Patients with Severe Hemophilia_A on Prophylaxis with Emicizumab By Thrombin Generation Assay
17. Endothelial Dysfunction and Altered Coagulation As Mediators of Thromboembolism in Behçet Disease
18. Effect of thrombopoietin-receptor agonists on a proliferation-inducing ligand (APRIL) plasma levels in patients with immune thrombocytopaenia
19. The Importance of Platelet Glycoside Residues in the Haemostasis of Patients with Immune Thrombocytopaenia
20. Impact of COVID-19 Pandemic on Patients with Immune Thrombocytopaenia
21. Fibrin Polymerization Ability Influences Joint Condition in Patients with Severe Haemophilia
22. Glycoside Residues on Platelet's Surface Regulate Platelet Function, Apoptosis and Binding of Coagulation Complexes in Patients with Immune Thrombocytopaenia
23. Study of the Effect of Fibrinogen, Factor XIII and Recombinant Activated Factor VII in a Model of Trauma-Induced Coagulopathy
24. Thein Vitroprocoagulant Effects of Standard and Extended Half-Life Recombinant Factor IX Concentrates in Patients on Prophylaxis with Emicizumab
25. Thrombin Generation Related to Netosis in Patients with Systemic Lupus Erythematosus
26. COVID‐19 and telemedicine in haemophilia in a patient with severe haemophilia A and orthopaedic surgery
27. Pro-apoptotic properties and mitochondrial functionality in platelet-like-particles generated from low Aspirin-incubated Meg-01 cells
28. Insights into the Procoagulant Profile of Patients with Systemic Lupus Erythematosus without Antiphospholipid Antibodies
29. Paradoxical effect of SARS‐CoV‐2 infection in patients with immune thrombocytopenia
30. Clinical trials and Haemophilia during the COVID‐19 pandemic: Madrid's experience
31. Platelet and immune characteristics of immune thrombocytopaenia patients non‐responsive to therapy reveal severe immune dysregulation
32. Pro-apoptotic properties and mitochondrial functionality in platelet-like-particles generated from low Aspirin-incubated Meg-01 cells.
33. Next‐generation sequencing for the diagnosis ofMYH9‐RD: Predicting pathogenic variants
34. Paradoxical effect of SARS‐CoV‐2 infection in patients with immune thrombocytopenia.
35. Influence of pharmacodynamics of factor VIII on bleeding phenotype of children under long-term prophylactic regimen
36. Next‐generation sequencing for the diagnosis of MYH9‐RD: Predicting pathogenic variants.
37. Defining haemostatic safety zones for the practice of sport in patients with severe haemophilia by thromboelastography
38. Study of pharmacokinetic parameters of factor VIII by Bayesian estimation in Children and Adolescents with Severe Hemophilia
39. Thromboelastography may help tailoring prophylactic treatment in regards to the individual exercise-associated bleeding risk of patients with severe haemophilia
40. Immune thrombocytopenia - in defence of the platelet count. Response to Hill
41. Platelet Apoptosis and PAI-1 are Involved in the Pro-Coagulant State of Immune Thrombocytopaenia Patients Treated with Thrombopoietin Receptor Agonists.
42. COVID‐19 and telemedicine in haemophilia in a patient with severe haemophilia A and orthopaedic surgery.
43. Procoagulant profile in patients with immune thrombocytopenia
44. Factors Involved in Maintaining Haemostasis in Patients with Myelodysplastic Syndrome.
45. Platelet Apoptosis and PAI-1 are Involved in the Pro-Coagulant State of Immune Thrombocytopaenia Patients Treated with Thrombopoietin Receptor Agonists
46. Pharmacokinetics of Multiple Doses of rFVIIa in Patients with Hemophilia With and Without Inhibitors
47. Features of Microparticle-Associated Procoagulant Activity in Patients with Thrombocytopenias of Immune and Central Origin
48. Effect of thrombopoietin-receptor agonists on a proliferation-inducing ligand (APRIL) plasma levels in patients with immune thrombocytopaenia
49. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia
50. Effects Of Thrombopoietin Receptor Agonists On APRIL Plasma Levels In Patients With Immune Thrombocytopenia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.